ecancermedicalscience

Case Report

Near-complete response to low-dose ceritinib in recurrent infantile inflammatory myofibroblastic tumour

1 Apr 2021
Abhenil Mittal, Aarushi Gupta, Sameer Rastogi, Adarsh Barwad, Swati Sharma

Background: Infantile inflammatory myofibroblastic tumour (IMT) is rare and the majority are driven by anaplastic lymphoma kinase (ALK) rearrangements. Previous literature on the use of ALK inhibitors in paediatric IMTs is extremely limited with no published literature on the use in infants. Crizotinib and ceritinib are two ALK inhibitors which are available and have been used in IMTs; however, ceritinib is much more affordable in the low- and middle-income country (LMIC) setting than crizotinib.

Case: An 11-month-old child, who had undergone surgery for mesenteric IMT at the age of 3 months, had an unresectable recurrence with soft tissue deposits in the subdiaphragmatic location abutting the spleen and paravesical location. As surgery would have entailed splenectomy and partial cystectomy, she was treated with low-dose ceritinib (300 mg/m2/day) with which she had a near-complete response without any toxicity.

Discussion and conclusion: This is the first report of the use of ceritinib at a lower dose for infantile IMT having immense practical applications for the low- and middle-income setting.

Related Articles

Felipe Andrés Cordero da Luz, Eduarda da Costa Marinho, Camila Piqui Nascimento, Lara de Andrade Marques, Patrícia Ferreira Ribeiro Delfino, Rafael Mathias Antonioli, Marcelo José Barbosa Silva, Rogério Agenor de Araújo
Soumitra Shankar Datta, Soumita Ghose, Manisha Ghosh, Amruta Jain, Sumedha Mandal, Sayan Chakraborty, Carlo Caduff
Foziya Mohammed Hussien, Anissa Mohammed Hassen, Zinet Abegaz Asfaw, Aragaw Yimer Ahmed, Yeshimebet Ali Dawed, Ahmed Hussien Asfaw, Erkihun Tadesse Amsalu, Hamid Yimam Hassen
Isabel Saffie Vega, Jorge Sapunar Zenteno, Felipe Buscaglia Fernandez, Felipe Reyes Cosmelli, Rodrigo Lagos Chavez, Badir Chahuán Manzur